Rhythm Pharmaceuticals (RYTM) is up 15.6%, or $16.38 to $121.15.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Positive Phase 2 Trial Results Boost Rhythm Pharmaceuticals’ Outlook and Price Target
- Rhythm Pharmaceuticals price target raised to $140 from $127 at BofA
- Rhythm Pharmaceuticals rises 11.4%
- Rhythm Pharmaceuticals Announces Positive Phase 2 Trial Results
- Rhythm Pharmaceuticals’ setmelanotide shows efficacy in Phase 2 PWS trial